With recent impressive clinical results of targeted alpha therapy using 225Ac, significant effort has been directed towards providing a reliable and sufficient supply of 225Ac to enable widespread using of 225Ac-radiopharmaceuticals. TRIUMF has begun production of 225Ac via spallation of thorium metal with 480 MeV protons. As part of this program, a new 225Ac-production target system capable of withstanding the power deposited by the proton beam was designed and its performance simulated over a range of potential operating parameters. Special attention was given to heat transfer and stresses within the target components. The target was successfully tested in two irradiations with a 72–73 µA proton beam for a duration of 36.5 h. The decay corrected activity at end of irradiation (average ± standard deviation) was (524 ± 21) MBq (14.2 mCi) and (86 ± 13) MBq (2.3 mCi) for 225Ac and 225Ra, respectively. These correspond to saturation yields of 72.5 MBq/µA for 225Ac and 17.6 MBq/µA for 225Ra. Longer irradiations and production scale-up are planned in the future.

No abstract

tumor xenograft types. The mechanism of action involves induction of DNA double-stranded breaks and progression into apoptosis. These results strongly support the use of FPI-1434 in IGF-1R overexpressing cancers.

No abstract